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Abstract
The association of immunodeficiency-related vaccine-derived rubella virus (iVDRV) with cutaneous and visceral granu-
lomatous disease has been reported in patients with primary immunodeficiency disorders (PIDs). The majority of these
PID patients with rubella-positive granulomas had DNA repair disorders. To support this line of inquiry, we provide
additional descriptive data on seven previously reported patients with Nijmegen breakage syndrome (NBS) (n = 3) and
ataxia telangiectasia (AT) (n = 4) as well as eight previously unreported patients with iVDRV-induced cutaneous granu-
lomas and DNA repair disorders including NBS (n = 1), AT (n = 5), DNA ligase 4 deficiency (n = 1), and Artemis defi-
ciency (n = 1). We also provide descriptive data on several previously unreported PID patients with iVDRV-induced
cutaneous granulomas including cartilage hair hypoplasia (n = 1), warts, hypogammaglobulinemia, immunodeficiency,
myelokathexis (WHIM) syndrome (n = 1), MHC class II deficiency (n = 1), Coronin-1A deficiency (n = 1), X-linked
severe combined immunodeficiency (X-SCID) (n = 1), and combined immunodeficiency without a molecular diagnosis
(n = 1). At the time of this report, the median age of the patients with skin granulomas and DNA repair disorders was
9 years (range 3–18). Cutaneous granulomas have been documented in all, while visceral granulomas were observed in six
cases (40%). All patients had received rubella virus vaccine. The median duration of time elapsed from vaccination to the
development of cutaneous granulomas was 48 months (range 2–152). Hematopoietic cell transplantation was reported to
result in scarring resolution of cutaneous granulomas in two patients with NBS, one patient with AT, one patient with
Artemis deficiency, one patient with DNA Ligase 4 deficiency, one patient with MHC class II deficiency, and one patient
with combined immunodeficiency without a known molecular etiology. Of the previously reported and unreported cases,
the majority share the diagnosis of a DNA repair disorder. Analysis of additional patients with this complication may
clarify determinants of rubella pathogenesis, identify specific immune defects resulting in chronic infection, and may lead
to defect-specific therapies.
Keywords DNA ligase 4 deficiency . ataxia telangiectasia . Nijmegen breakage syndrome . Artemis deficiency . combined
immunodeficiency . chronic rubella infection resulting in cutaneous granuloma formation
Introduction
The long-term presence of immunodeficiency-related vac-
cine-derived rubella virus (iVDRV) in association with cuta-
neous and sometimes visceral granuloma formation was re-
cently identified using deep sequencing of lesions [1] and then
extended by rubella-targeted testing in a total of 19 patients
with various primary immunodeficiency disorders (PIDs)
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[1–4]. Based on the clinical and laboratory features, it has
been hypothesized that underlying immunodeficiency
allowed for persistence of the attenuated rubella virus vaccine
strain. Polarization of the macrophages to a M2 phenotype
appears to be associated with an inability to clear the virus
[2]. Aberrant cytotoxic CD8+ T cell responses also appear to
be important in the persistence of rubella virus in association
with cutaneous granuloma formation [2]. Interestingly, the
majority of PID patients with rubella-positive granulomas
had DNA repair disorders such as ataxia telangiectasia (AT)
(n = 9), Nijmegen breakage syndrome (NBS) (n = 3), or V(D)J
recombination defects such as RAG1 (n = 1) and RAG2 (n =
1) deficiency [1–4].
DNA repair disorders encompass a spectrum of PIDs
inc luding AT, NBS, XRCC4-l ike fac tor (XLF) /
Cernunnos, Bloom’s syndrome (BS), DNA ligase 4 defi-
ciency, and Artemis deficiency. The importance of DNA
repair by homologous recombination, non-homologous
end joining (NHEJ), and cell cycle checkpoint control is
underscored by its crucial role in the development of the
adaptive immune system. Processes involving NHEJ such
as V(D)J recombination and associated development of T
and B cell receptor diversity is one such example. It is
unknown, however, how DNA repair disorders are permis-
sive for the salient features that have been hypothesized to
permit the development of iVDRV infection often present-
ing as chronic cutaneous granulomas (see Fig. 1). The po-
tential impact of DNA repair disorders on cytotoxic CD8+
T cell responses and macrophage polarity are intriguing
areas that warrant more detailed evaluation.
Methods
To support the importance of this line of inquiry, we provide
additional information on previously reported patients (three
patients with NBS and four patients with AT) and iVDRV-
associated cutaneous granulomatous disease as well as eight
not yet reported patients with DNA repair disorders and
iVDRV-associated cutaneous granulomatous disease (one pa-
tient with NBS, five patients with AT, one patient with DNA
ligase 4 deficiency, and one patient with Artemis deficiency).
To our knowledge, the latter two disorders have not yet been
associated with this complication. We are also including six
not yet reported patients with other combined immunodefi-
ciencies and iVDRV cutaneous granuloma formation (one pa-
tient each with cartilage hair hypoplasia (CHH), warts,
hypogammaglobulinemia, immunodeficiency, myelokathexis
(WHIM) syndrome, MHC class II deficiency, Coronin-1A
deficiency, X-linked severe combined immunodeficiency
(X-SCID), and combined immunodeficiencywithout a known
molecular cause).
Patients with a PID diagnosis with cutaneous granulomas
that were rubella virus-positive were identified though the
Clinical Immunology Society Listserve which is a tool utilized
by the physician and scientist members of this professional
society to enhance collaboration and exchange information
focused on PID patients. The authors also identified relevant
cases following a literature search or personal communication.
Physicians were individually contacted. A structured
datasheet was utilized to collect clinical information from
treating physicians.
Fig. 1 a Macroscopic features in
patient no. 21 with acute and
chronic ulcerations of the cheek
and destruction of the nasal
cartilage. b, c Histopathology of
lesional skin in patient no. 21with
granulomatous dermatitis—H&E




demonstrating the presence of
rubella virus capsid (red) in
Lanrgerhans’ giant cells (green)
in patient no. 21
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Results
Table 1 provides a description of the clinical and immunolog-
ical characteristics of iVDRV-associated cutaneous granulo-
matous disease patients with DNA repair disorders (n = 15)
and other PIDs (n = 6).
Demographic Features
The median age at the time of report of the patients with DNA
repair disorders (n = 15) was 9 years (range 3–18). The ma-
jority were females (73%). For patients with other PIDs (n =
6), the median age at the time of report was 17 years (range 3–
33). The majority were also females (67%).
Clinical and Immunologic Features
Cutaneous granuloma formation has been documented in all 15
DNA repair disorder cases while visceral granuloma formation
impacting the spleen, liver, bone, and lungs were observed in six
cases (40%). The severity of the cutaneous granulomas was
variable including superficial lesions as well as deep ulcerating
lesions and destruction of soft tissues (Fig. 1). Among patients
with other PIDs, only cutaneous granuloma formation has been
documented. T cell and B cell lymphopenia as well as
hypogammaglobulinemia or impaired antibody formation was
present in the majority of patients with DNA repair disorders
consistent with a combined immunodeficiency phenotype. Four
AT patients demonstrated a hyper IgM phenotype. Moreover, T
cell and B cell lymphopenia was also present in the majority of
patients with other PIDs. Among DNA repair disorder patients
and other PIDs, the median age at onset of cutaneous granuloma
formation was 54 months (range 14–168) and 151 months
(range 22–324), respectively. The median duration of time
elapsed from vaccination to the development of cutaneous gran-
uloma formation in these two groups was 48 months (range 2–
152) and 102months (range 13–135), respectively. Two patients
with DNA repair disorders developed cutaneous granulomas
following chemotherapy for lymphoma (both AT patients).
The presence of rubella was confirmed in all skin and visceral
granulomas. The diagnosis of rubella was made by PCR (47%)
or immunohistochemistry (53%) in patients with DNA repair
disorders. For patients with other PIDs, the diagnosis of rubella
was made by PCR in the majority of cases (83%).
Treatments and Outcomes
Among DNA repair disorder patients, treatments included top-
ical corticosteroids (53%), hematopoietic stem cell transplanta-
tion (33%), and nitazoxanide (27%). Similarly, among patients
with other PIDs, treatments included topical (n = 1) and sys-
temic corticosteroids (n = 1) or both (n = 1). One patient dem-
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factor therapy. Hematopoietic stem cell transplantation was re-
ported to result in scarring resolution of granulomata including
two patients with NBS, one patient with AT, one patient with
Artemis deficiency, one patient with DNA Ligase 4 deficiency,
one patient with MHC class II deficiency, and one patient with
combined immunodeficiency without a known molecular
cause [4]. Rubella-associated complications did not contribute
to death among those patients who died (40%).
Discussion
The majority of the previously reported (14 of 19) and not yet
reported (8 of 14) cases listed here share the clinical diagnosis
of a DNA repair disorder and the presence of rubella virus,
strongly suggesting the association between iVDRVand cuta-
neous granuloma formation. The addition of patients with
DNA ligase 4 and Artemis deficiency to the existing literature
of PIDs (i.e., AT, NBS, RAG1/RAG2 deficiency) with cuta-
neous granuloma formation in association with chronic rubel-
la virus infection [1–4] suggests that aberrations in the genes
involved in DNA repair result in a specific deficient immune
response that places these patients at risk for the development
of this complication. However, the presence of iVDRV-
associated granulomatous disease in other PIDs may indicate
a general predisposition of patients with combined immuno-
deficiencies who are not severe enough to be diagnosed before
the initiation of live viral vaccines.
Common to all of these patients is the presence of a signif-
icant T cell deficiency. For many, there is also a concomitant
antibody deficiency. Although not much is known about rubel-
la virus-specific T cell responses, we hypothesize that adequate
rubella virus-specific T cell responses are vital to the control of
rubella virus. Likely common to many of these patients is the
presence of rubella virus-specific antibodies. Since many of
these patients were recipients of immunoglobulin prophylaxis
with concomitant levels of rubella virus-specific antibodies re-
flective of the immunoglobulin donor pool, it appears that ru-
bella virus-specific antibody is not able to eliminate persistent
infection. Moreover, no cases of rubella virus-associated gran-
ulomas have been described in patients with agammaglobulin-
emia, and intravenous immunoglobulin does not appear to be
an effective treatment of cutaneous granulomas.
Although a prominent T cell deficiency and concomitant
antibody deficiency are common to the majority of these pa-
tients, the significant variability that exists even among specific
diagnoses supports the importance of these aforementioned im-
munological lacunae in the pathogenesis of iVDRV-associated
cutaneous granulomatous disease. For example, among patients
with AT, there is a wide spectrum of symptoms, but granulo-
matous disease is not a frequent clinical finding. Moreover, the
vast majority of the AT patients represented here have docu-
mented clinical and laboratory evidence of significant and pro-
found immunodeficiency and immune dysregulation. This
includes end organ autoimmunity and lymphoproliferation as
well as interesting features such as abnormal isotype switching
resulting in a hyper IgM phenotype and lack of anti-rubella IgG
antibody formation [5]. Additional data focusing on detailed
immunological evaluation among unbiased cohorts of patients
(e.g., AT patients) without iVDRV-associated granulomatous
disease would be a useful comparison.
The period of latency between vaccination and the evolu-
tion of iVDRV-associated cutaneous granulomatous disease
was wide. Notably, the period of latency was shorter among
patients with DNA repair disorders when compared with pa-
tients suffering from other PIDs. We hypothesize that the im-
munologic status of the patient plays an important role in
shaping this period of latency. For example, diminution of
CD8+ T cell cytotoxicity or the T cell repertoire over time
may be forces favoring the persistence of vaccine-associated
rubella virus and the subsequent development of cutaneous
granulomatous disease. The presence of additional host fac-
tors (e.g., the receipt of cytotoxic chemotherapeutic agents in
some of the reported patients), environmental factors, and
pathogen-specific factors (e.g., viral escape mechanisms to
include the accumulation of mutations by the virus) may also
influence the risk for the development of this complication
and the timing of its development in individual patients.
We acknowledge the limitations imposed by our study de-
sign and the possibility that there may be a selection bias such
that patients with DNA repair disorders and cutaneous granu-
loma formation may be over-represented. We can only specu-
late as to the risk for iVDRV-associated cutaneous granuloma
formation in DNA repair disorders and other combined immu-
nodeficiencies. We acknowledge that no exact evidence exists
that proves that rubella virus causes cutaneous granulomatous
disease. It is clear, however, that rubella virus can be demon-
strated in granulomas of patients with PIDs including patients
with DNA repair disorders. For these PID patients, vaccination
exposure preceded the development of cutaneous granuloma-
tous disease. Indeed, there is a body of literature describing the
presence of cutaneous granulomatous disease of unknown eti-
ology in the context of disorders such as Artemis, DNA-
dependent protein kinase (DNA-PK), and RAG deficiencies
[1, 6, 7]. Careful evaluation of these cases for the presence of
chronic rubella virus infection may be a productive clinical
exploration. Moreover, confirmation of the presence of rubella
virus strain RA27/3 is necessary.Many of these analyses can be
achieved through the application of immunohistochemical
staining and more sensitive techniques including RT-PCR.
Analysis on fresh tissue is desirable as extraction of intact
RNA from formalin-fixed paraffin-embedded is limited.
This relatively common association underscores the risk of
live viral vaccination in patients with these disorders. If the di-
agnosis of a primary immunodeficiency disorder is known at the
time of vaccination (e.g., AT), rubella virus vaccine should only
be given in full awareness of this potential complication.
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Moreover, the presence of chronic granulomatous lesions should
prompt aggressive pathogen identification to include rubella vi-
rus. Consideration should be given to use of curative treatment
with hematopoietic stem cell transplantation using modified re-
duced intensity conditioning in selected patients with DNA re-
pair disorders [8]. Other areas of active exploration include the
use of agents such as nitazoxanide that may possess broad anti-
viral properties [9]. Interestingly, the responses reported post-
conditioning among several of the NBS patients, one AT patient,
one DNA ligase 4-deficient patient, and one Artemis-deficient
patient suggests that the elimination of rubella virus-specific
(functionally impaired) effector T cells may have resulted in
the disappearance of the cutaneous granulomatous disease. We
anticipate that the rubella virus itself remains; however, the
engrafted donor immune system is then able to control the ru-
bella virus as would be anticipated in the normal host.
Additional basic and clinical research analyses of con-
firmed patients with DNA repair disorders and other PIDs
with iVDRV as well as cutaneous and visceral granuloma
formation are planned. A focus of these analyses will include
the evaluation of the cellular and humoral immune response to
rubella vaccination. These efforts will help clarify those deter-
minants that influence rubella pathogenesis, as new patients
continue to be identified retrospectively and prospectively.
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